Key result
Recent progress in restrictive cardiomyopathy research from clinical and translational studies provides insights into the mechanisms underlying its etiology and development.
This review summarizes recent clinical and translational research on restrictive cardiomyopathy to enhance understanding of its molecular mechanisms and guide future treatment strategies.
May inform restrictive cardiomyopathy strategies; leaves open translation of molecular insights to practice.
Cardiomyopathies are diseases that primarily affect the myocardium, leading to serious cardiac dysfunction and heart failure. Out of the three major categories of cardiomyopathies (hypertrophic, dilated and restrictive), restrictive cardiomyopathy (RCM) is less common and also the least studied. However, the prognosis for RCM is poor as some patients dying in their childhood. The molecular mechanisms behind the disease development and progression are not very clear and the treatment of RCM is very difficult and often ineffective. In this article, we reviewed the recent progress in RCM research from the clinical studies and the translational studies done on diseased transgenic animal models. This will help for a better understanding of the mechanisms underlying the etiology and development of RCM and for the design of better treatments for the disease.
No takes yet. Share an insight, caveat, or question.
Pierre-Yves et al. (2011) conducted a review in Restrictive cardiomyopathy. Recent progress in restrictive cardiomyopathy research from clinical and translational studies provides insights into the mechanisms underlying its etiology and development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: